Research Focus

Former Employee. GRADUATE STAFF; Chief Resident

Recent additions – View all

1. Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

   Research Letter

   Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
   Blood (2023)

   Fulltext@MSK | Save
2. Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis

   Meeting Abstract

   Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
   Blood (2021)

   Fulltext@MSK | Save
3. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia

   Meeting Abstract

   Grenet, J.; Jain, A. G.; Burkart, M.; Waksal, J.; Famulare, C.; Numan, Y.; Stahl, M.; Mckinnell, Z.; Ball, B.; Ma, X.; more...
   Blood (2021)

   Fulltext@MSK | Save